Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present HemaCare Corp. (OTC: HEMA).

Full DD Report for HEMA

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-139.269.349.409.0811,951
2018-12-1210.089.0610.089.0611,800
2018-12-119.509.479.509.055,200
2018-12-109.979.999.999.971,381
2018-12-0710.6710.0010.679.255,814

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-124,70011,80039.8305Short
2018-12-113,5005,20067.3077Short
2018-12-107601,38155.0326Short
2018-12-073,6775,71464.3507Short
2018-12-0656088163.5641Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HEMA.


About HemaCare Corp. (OTC: HEMA)

Logo for HemaCare Corp. (OTC: HEMA)

HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through years in the business of blood collection, processing and storage. In addition we have established a robust donor recruitment and management system which supports an extensive registry of well characterized repeat donors. HemaCare s controlled procedures ensure a readily available inventory of high quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCare s products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes phenotypic or disease state, for example , or sub sets of immune cells that can be selected in our laboratory using the latest technology. HemaCare s products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies.

 

Contact Information

 

 

Current Management

  • Pete van der Wal / President, CEO
  • Rochelle Martel / Corporate Secretary, CFO
  • Nestor Montano / Corporate Controller
  • Steve B Gerber, MD / Chairman
  • James G. Wolf / Director, Audits, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Gil Avidar /
  • George Scholl / Compensation Committee Member
  • Terry Van Der Tuuk / Audit Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $70,837,830 - 03/09/2018
  • Authorized: 40,000,000 - 12/31/2016
  • Issue and Outstanding: 11,612,759 - 06/30/2017

 


Recent Filings from (OTC: HEMA)

Annual Report - 2017 Audited Financial Statements
Filing Type: Annual Report - 2017 Audited Financial StatementsFiling Source: OTC Markets
Filing Date: March, 08 2018

 

 


Daily Technical Chart for (OTC: HEMA)

Daily Technical Chart for (OTC: HEMA)


Stay tuned for daily updates and more on (OTC: HEMA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HEMA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HEMA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HEMA and does not buy, sell, or trade any shares of HEMA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/